Ziopharm Oncology Inc. (NASDAQ:ZIOP) Stock Takes a Hit: A Good Buy Now?
Ziopharm Oncology Inc. (NASDAQ:ZIOP) fell 16% after announcing Q2 2021 corporate updates. Interim CEO Heidi Hagen said that Ziopharm had made considerable progress on various fronts since the last update. The company had built positive momentum in the TCR-T Library clinical study enabling activities and strengthening the balance sheet. He explained that the quarterly update shows that the company is on track with what it had early set to attain….